Atrial Fibrillation Risk and New HCM Therapies

from Tales from the Heart · host Hypertrophic Cardiomyopathy Association / Lisa Salberg

Lisa Salberg and Dr. Ethan Rowin break down new data on atrial fibrillation risk in patients taking myosin inhibitors for HCM. They explain what the latest research shows, how risk compares to traditional care, and what patients should watch for as treatment options continue to evolve. This conversation was recorded April 28, 2026.

Episode metadata supplied by the publisher feed · Published May 5, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Atrial Fibrillation Risk and New HCM Therapies

0:00 29:30

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Tales from the Heart?

This episode is 29 minutes long.

When was this Tales from the Heart episode published?

This episode was published on May 5, 2026.

Can I download this Tales from the Heart episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!